# ACS Medicinal Chemistry Letters

Letter

Subscriber access provided by LAURENTIAN UNIV

# Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors

Christopher James Bungard, Peter D. Williams, Jurgen Schulz, Catherine M. Wiscount, M. Katharine Holloway, Marie Loughran, Jesse J. Manikowski, Hua-Poo Su, David Jonathan Bennett, Lehua Chang, Xin-jie Chu, Alejandro Crespo, Michael P. Dwyer, Kartik Keertikar, Gregori Joseph Morriello, Andrew W Stamford, Sherman T. Waddell, Bin Zhong, Bin Hu, Tao Ji, Tracy L Diamond, Carolyn Bahnck-Teets, Steven S. Carroll, John F. Fay, Xu Min, William J Morris, Jeanine E. Ballard, Michael D. Miller, and John A McCauley *ACS Med. Chem. Lett.*, Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.7b00386 • Publication Date (Web): 13 Nov 2017 Downloaded from http://pubs.acs.org on November 14, 2017

#### **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Medicinal Chemistry Letters is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors

Christopher J. Bungard,\*<sup>a</sup> Peter D. Williams,<sup>a</sup> Jurgen Schulz,<sup>a</sup> Catherine M. Wiscount,<sup>a</sup> M. Katharine Holloway,<sup>a</sup> H. Marie Loughran,<sup>a</sup> Jesse J. Manikowski,<sup>a</sup> Hua-Poo Su,<sup>a</sup> David J. Bennett,<sup>a</sup> Lehua Chang,<sup>b</sup> Xin-Jie Chu,<sup>b</sup> Alejandro Crespo,<sup>b</sup> Michael P. Dwyer,<sup>b</sup> Kartik Keertikar,<sup>b</sup> Gregori J. Morriello,<sup>b</sup> Andrew W. Stamford,<sup>b</sup> Sherman T. Waddell,<sup>b</sup> Bin Zhong,<sup>c</sup> Bin Hu,<sup>c</sup> Tao Ji,<sup>c</sup> Tracy L. Diamond,<sup>a</sup> Carolyn Bahnck-Teets,<sup>a</sup> Steven S. Carroll,<sup>a</sup> John F. Fay,<sup>a</sup> Xu Min,<sup>a</sup> William Morris,<sup>b</sup> Jeanine E. Ballard,<sup>a</sup> Michael D. Miller,<sup>a</sup> and John A. McCauley.<sup>a</sup>

<sup>a</sup>Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, PA 19486, USA.

<sup>b</sup>Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.

<sup>c</sup>WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China.

KEYWORDS: HIV-1 protease inhibitors, MK-8718, PL-100, piperazine sulfonamide.

**ABSTRACT:** Using the HIV-1 protease binding mode of **MK-8718** and **PL-100** as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core showed an 60-fold increase in enzyme binding affinity and a 10-fold increase in antiviral activity relative to **MK-8718**.

HIV-1 protease is a critical enzyme in the lifecycle of the virus, serving to catalyze the proteolytic cleavage of polypeptide precursors into mature enzymes and structural proteins that are essential components of HIV-1.1 Inhibitors of this enzyme prevent conversion of HIV-1 particles into their mature infectious form, and so it follows that HIV-1 protease inhibitors represent an important therapeutic approach for the treatment of HIV-1 infection.<sup>2-4</sup> Recently, we reported the discovery of MK-8718, an HIV-1 protease inhibitor containing a novel morpholine aspartate binding group.<sup>5</sup> A key feature of this inhibitor is that the morpholine amine forms the key interaction with the Asp-25<sub>A</sub> and Asp-25<sub>B</sub> acidic residues of the enzyme, in contrast to the majority of inhibitors where a hydroxyl group plays this role.<sup>6</sup> Herein we report further optimization of the enzyme bound conformation of these amine based class of inhibitors.

Inspiration for the design of our next generation inhibitors came from examining the enzyme bound conformations of  $MK-8718^5$  and  $PL-100^7$  (Figure 1). It can be seen that the morpholine oxygen of MK-8718 binds to the flap of the enzyme (Ile50<sub>A</sub> and Ile50<sub>B</sub>) via a bridging water. In contrast, the sulfonamide moiety present in PL-100 binds directly to the Ile50<sub>A</sub> and Ile50<sub>B</sub> residues. This observation led us to design the hybrid core shown below in Figure 1. The so designed piperazine sulfonamide would retain the amine to form the key interaction with the Asp-25<sub>A</sub> and Asp-25<sub>B</sub> acidic residues, while the sulfonyl group would displace the bridging water and bind directly to the flap Ile50<sub>A</sub> and Ile50<sub>B</sub> residues. In

order to simplify the synthesis of the initial proof of principal target, a simplified right hand side derived from 3,3-bis(4fluorophenyl)propanoic acid was utilized.<sup>8</sup> Synthesis of our initial design is outlined in Scheme 1. Commercially available racemic 1 was sulfonylated to afford piperazine sulfonamide 2. Dess-Martin oxidation<sup>9</sup> gave aldehyde 3 which underwent Wittig olefination using (2-nitrobenzyl)triphenylphosphonium bromide<sup>10</sup> to afford olefin 4. Concomitant reduction of the nitro and olefin functionalities under hydrogenation conditions vielded aniline 5. Coupling of 3,3-bis(4fluorophenyl)propanoic acid with aniline 5 afforded amide 6. Elaboration to the desired target was achieved by Bocdeprotection and resolution of the ensuing enantiomers to afford 7 and 8. Antiviral activity of both enantiomers 7 and 8 was measured and pleasingly enantiomer 7 showed significant activity in a cell based antiviral assay (EC<sub>50</sub> = 27 nM).<sup>11</sup> With this active compound in hand, we decided to pursue an x-ray crystal structure of 7 bound to HIV-1 protease to confirm our hypothesis that the sulfonamide moiety had displaced the water molecule present in the enzyme bound structure of MK-8718. Gratifyingly, the crystal structure of 7 bound to HIV-1 protease, shown in Figure 2, indeed showed that no bridging water was present, and the sulfone of 7 was directly hydrogen bonded to the Ile50<sub>A</sub> and Ile50<sub>B</sub> residues of the enzyme. Also evident from the crystal structure of 7 was that the preferred stereochemistry at the 2-position of the piperazine moiety was the (S)-



Figure 1. Hybrid design concept based on the binding modes of MK-8718 and PL-100 (pdb codes 5IVT and 2QMP).



#### Scheme 1<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) PhSO<sub>2</sub>Cl, Hunig's base, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C to RT; (b) Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (c) K<sub>2</sub>CO<sub>3</sub>, 18crown-6, (2-nitrobenzyl)triphenylphosphonium bromide, DME, RT; (d) Pearlman's catalyst, H<sub>2</sub> balloon, CF<sub>3</sub>CH<sub>2</sub>OH, RT; (e) 3,3-Bis(4fluorophenyl)propanoic acid, T3P<sup>®</sup>, Hunig's base, EtOAc, RT; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT, then Chiralpak<sup>®</sup> AD.

configuration, opposite to that which is preferred for the morpholine core of **MK-8718**. This was in concurrence with results from earlier modelling studies of the piperazine sulfonamide core, which showed the HIV-1 protease binding conformation of the (S)-enantiomer to be lower in energy than that of the corresponding (R)-enantiomer. Although piperazine sulfonamide **7** displayed good antiviral activity, *in vitro* metabolic studies revealed that the unsubstituted left hand side of the

piperazine ring was susceptible to significant metabolic oxidation. This prompted us to investigate whether functionalization of the unsubstituted side of the piperazine ring would be tolerated with respect to antiviral activity. In order to introduce a methyl group on the left hand side of the piperazine in a regioand stereo-controlled manner, the route shown in Scheme 2 was utilized.<sup>12</sup> The route starts


Figure 2. X-ray crystal structure of 7 bound to HIV-1 protease showing hydrogen bonding to Ile50<sub>A</sub> and Ile50<sub>B</sub> residues.



#### Scheme 2<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) LiAlH<sub>4</sub>, 2-Me-THF, 0 °C; (b) K<sub>2</sub>CO<sub>3</sub>, 18-crown-6, (2-nitrobenzyl)triphenylphosphonium bromide, DME, RT; (c) Pearlman's catalyst, 50 psi H<sub>2</sub>, EtOAc/MeOH, RT; (d) 3,3-Bis(4-fluorophenyl)propanoic acid, T3P®, Hunig's base, EtOAc, RT; (e) TFA, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>; RT; (f) (i) PhSO<sub>2</sub>Cl, NEt<sub>3</sub>, DMF, 0 °C; (ii) Diazene-1,2-diylbismorpholinomethanone, PBu<sub>3</sub>, THF, RT; (g) (*R*)-2-Aminopropan-1-ol, 1,2-DCE, 40 °C; (h) (i) Boc<sub>2</sub>O, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT; (ii) Diazene-1,2-diylbismorpholinomethanone, PBu<sub>3</sub>, THF, RT; (j) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT.

with readily available and configurationally stable Weinreb amide 9. Reduction of 9 afforded aldehyde ,<sup>13</sup> which underwent Wittig olefination to give 11. Reduction of both the olefin and nitro groups afforded aniline 12, which was coupled with 3,3-bis(4-fluorophenyl)propanoic acid to afford amide 13. Deprotection of 13 afforded amino alcohol 14 which was converted to aziridine 15 *via* a sulfonylation and subsequent intramolecular Mitsunobu<sup>14</sup> reaction. Opening of aziridine 15 with (*R*)-2-aminopropan-1-ol, followed by Boc-protection afforded 16, which was converted to piperazine 17 *via* an intramolecular Mitsunobu reaction. Boc-deprotection afforded the desired target **18**. Aziridine **15** was used to synthesize all four methyl-substituted isomers as shown in Figure 3. Although **20** and **21** with methyl substituents at the 6-position of the piperazine showed similar potency to unsubstituted piperazine 7, we were intrigued by the x-ray crystal structure of the less potent analogue **18** bound to HIV-1 protease, as shown in Figure 4. It can be seen that the phenyl group on the sulfonamide moiety and the me-



Figure 4. X-ray crystal structure of 18 bound to HIV-1 protease showing steric clash leading to design of a bicyclic piperazine.

thyl group on the piperazine ring lie in close proximity to each other, likely creating an unfavorable steric interaction in the binding conformation of the molecule. This observation led us to consider forming a bicyclic ring, with a bond joining the sulfone to the piperazine ring. Molecular modelling suggested a three carbon chain length would be optimal for locking the molecule in the bioactive conformation. Synthesis of this target is shown in Scheme 3 and began with commercially available amino alcohol 22. Aziridine formation via sulfonylation and Mitsunobu ring closure afforded intermediate 23. Aziridine 23 was opened with (R)-2-aminopent-4-en-1-ol and subsequent Boc-protection yielded 24. An intramolecular Mitsunobu reaction gave piperazine 25 and subsequent magnesium/MeOH mediated deprotection<sup>15</sup> cleanly removed the phenylsulfonyl moiety in the presence of both the NBoc and OBn moieties to give 26. Sulfonylation of 26 gave metathesis precursor 27 which underwent ring closure mediated by Zhan Catalyst-1B<sup>16</sup> to give bicyclic compound **28**. Hydrogenation of

**28** reduced the olefin and removed the benzyl group yielding 29. Dess-Martin oxidation, followed by Corev Fuchs alkyne formation<sup>17</sup> via dibromide **31** afforded alkyne **32**. Sonogashira coupling,<sup>18</sup> followed by reduction of so formed **33** afforded aniline 34. Coupling 3,3-bis(4-fluorophenyl)propanoic acid with aniline 34 and subsequent Boc-deprotection gave the bicyclic target 35. We were pleased to observe that bicyclic compound 35 retained good antiviral activity (EC<sub>50</sub> = 21nM).<sup>11</sup> The x-ray crystal structure of **35** bound to HIV-1 protease, as shown in Figure 5, revealed the expected binding mode, whereby the sulfonyl group forms hydrogen bonds directly to flap Ile50A and Ile50B residues, taking the place of the bridging water present in the crystal structure of MK-8718 bound to HIV-1 protease. With this new core in hand, we decided to incorporate the highly optimized pieces of MK-8718 into a molecule containing this core. The synthesis was carried out starting with alkyne 32 as shown in Scheme 4. Sonogashira coupling, followed by



#### Scheme 3<sup>a</sup>

<sup>a</sup> (a) (i) PhSO<sub>2</sub>Cl, NEt<sub>3</sub>, DMF, 0 °C; (ii) DIAD, PBu<sub>3</sub>, THF, 0 °C; (b) (i) (*R*)-2-Aminopent-4-en-1-ol, THF, 45 °C; (ii) Boc<sub>2</sub>O, NEt<sub>3</sub>, CH<sub>3</sub>CN, 45 °C; (c) DIAD, PBu<sub>3</sub>, THF, RT; (d) Mg, MeOH, sonication, RT; (e) 2-Chloroethanesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT; (f) Zhan Catalyst-1B, 1,2-DCE, 50 °C; (g) Pearlman's catalyst, H<sub>2</sub> balloon, EtOAc, RT; (h) Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, RT; (i) PPh<sub>3</sub>, CBr<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT; (j) EtMgBr, THF, 0 °C; (k) 3-Fluoro-2-iodoaniline, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, NEt<sub>3</sub>, CH<sub>3</sub>CN, 70 °C; (l) Pearlman's catalyst, H<sub>2</sub> balloon, EtOH, RT; (m) (i) 3,3-Bis(4-fluorophenyl)propanoic acid, T3P®, Hunig's base, EtOAc, RT; (ii) HCl, dioxane, RT.



Figure 5. Antiviral activity  $(EC_{50})^{11}$  and X-ray crystal structure of 35 bound to HIV-1 protease.

reduction afforded amine **36**. Coupling of amine **36** with (2S,3S)-2-azido-3-(4-chlorophenyl)-3-(3,5-

difluorophenyl)propanoic acid<sup>5</sup> gave amide **37**, which, after azide reduction and Boc-deprotection produced thefinal compound **38**. This compound showed exquisite enzyme binding affinity (IC<sub>50</sub> = 12 pM) for HIV-1 protease,

Scheme 4<sup>a</sup>



<sup>a</sup>Reagents and conditions: (a) (i) 5-Fluoro-4-iodopyridin-3-amine, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, NEt<sub>3</sub>, CH<sub>3</sub>CN, 70 °C; (ii) Pearlman's catalyst, H<sub>2</sub> balloon, EtOH, RT; (b) (*2S*,*3S*)-2-azido-3-(4-chlorophenyl)-3-(3,5-difluorophenyl)propanoic acid, POCl<sub>3</sub>, pyridine, 0 °C; (c) (i) PMe<sub>3</sub>, THF/H<sub>2</sub>O, 0 °C; (ii) HCl, dioxane/CH<sub>2</sub>Cl<sub>2</sub>, RT.

which translated into potent antiviral activity ( $EC_{50} = 2.8 \text{ nM}$ ) in a cell based assay. As shown in Table 1, this represents a significant potency improvement relative to MK-8718 (binding  $IC_{50} = 700 \text{ pM}$ , antiviral  $EC_{50} = 27 \text{ nM}$ ). In addition, the potency of **38** compares favorably to market leading HIV-1 protease inhibitors Atazanavir and Darunavir.

In summary, through a series of structure based design iterations, a novel bicyclic piperazine sulfonamide aspartyl protease binding core was identified. This core produced an 60-fold increase in HIV-1 protease binding affinity and a 10-fold increase in antiviral activity relative to **MK-8718**.

Table 1. Enzyme affinity and antiviral activity of key molecules

Г., 19	11
Enzyme	Antiviral
IC <sub>50</sub> (pM)	EC <sub>50</sub> (nM)
$700 \pm 600$	$27\pm7$
$12 \pm 1$	$2.8\pm0.4$
$40 \pm 30$	$12 \pm 4$
$13 \pm 3$	$7\pm2$
	$IC_{50} (pM)$ $700 \pm 600$ $12 \pm 1$ $40 \pm 30$ $13 \pm 3$

#### ASSOCIATED CONTENT

#### Supporting Information

Synthetic experimental details for the synthesis of 7, 8, 18 - 21, and 35, descriptions of primary biological assays, procedures for co-crystallization studies, and a table of crystallographic statistics, along with *in vivo* rat pharmacokinetic data for 7, 18, 20, and 21 are available free of charge (PDF) on the ACS Publications website at DOI: xxxxxx. X-ray crystallographic data for 7, 18, 19, 20, 21, and 35 bound to HIV-1 protease have been deposited in the RCSB protein data bank (pdb codes 6B36, 6B3C, 6B3F, 6B38, 6B3G, 6B3H).

#### AUTHOR INFORMATION

#### **Corresponding Author**

\* E-mail: christopher\_bungard@merck.com Phone: 215-652-5002

## ABBREVIATIONS

HIV = human immunodeficiency virus; Ile = isoleucine; Asp = aspartic acid; Boc = *tert*-butyloxycarbonyl; 1,2-DCE = 1,2-dichloroethane; DIAD = diisopropyl azodicarboxylate; DME = 1,2-dimethoxyethane; DMF = dimethylformamide; EtOAc = ethyl acetate; MeOH = methanol; NEt<sub>3</sub> = triethylamine; PBu<sub>3</sub> = tributylphosphine; RT = room temperature;  $T_3P$ ® = 1-propanephosphonic anhydride; THF = tetrahydrofuran; TFA = trifluoroacetic acid.

## REFERENCES

(1) Erickson-Viitanen, S.; Manfredi, J.; Viitanen, P.; Tribe, D. E.; Tritch, R.; Hutchison, C. A., 3rd; Loeb, D. D.; Swanstrom, R., Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. *AIDS Res Hum Retroviruses* **1989**, 5, (6), 577-91.

(2) Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S., Active human immunodeficiency virus protease is required for viral infectivity. *Proc. Natl. Acad. Sci. U. S. A.* **1988**, 85, (13), 4686-90.

(3) Ghosh, A. K.; Osswald, H. L.; Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. *J. Med. Chem.*, **2016**, 59 (11), 5172–5208.

(4) Midde, N. M.; Patters, B. J.; Rao, P.; Cory, T. J.; Kumar, S. Investigational protease inhibitors as antiretroviral therapies. *Expert Opin. Investig. Drugs*, **2016**, 25 (10), 1189–1200.

(5) Bungard, C. J.; Williams, P. D.; Ballard, J. E.; Bennett, D. J.; Beaulieu, C.; Bahnck-Teets, C.; Carroll, S. S.; Chang, R. K.; Dubost, D. C.; Fay, J. F.; Diamond, T. L.; Greshock, T. J.;Hao, L.; Holloway, K. M.; Felock, P. J.; Gesell, J. J.; Su, H.; Manikowski, J. J.; McKay, D. J.; Miller, M.; Min, X.; Molinaro, C.; Moradei, O. M.; Nantermet, P. J.; Nadeau, C.; Sanchez, R. I.; Satyanarayana, T.; Shipe W. D.; Sanjay, S. K.; Truong, V. L.; Vijayasaradhi, S.; Wiscount, C. M.; Vacca, J. P.; Crane, S. N.; McCauley, J. A. Discovery of MK-8718, an HIV-1 protease inhibitor containing a novel morpholine aspartate binding group. ACS Med. Chem. Lett., **2016**, 7 (7), 702–707.

(6) Jaskolski, M.; Tomasselli, A. G.; Sawyer, T. K.; Staples, D. G.; Heinrikson, R. L.; Schneider, J.; Kent, S. B.; Wlodawer, A., Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor, *Biochemistry* **1991**, 30, (6), 1600-9.

(7) Dandache, S.; Coburn, C. A.; Oliveira, M.; Allison, T. J.; Holloway, M. K.; Wu, J. J.; Stranix, B. R.; Panchal, C.; Wainberg, M. A.; Vacca, J. P. J. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an *in vitro* selection study. *Med. Virol.* **2008**, 12, 2053-63.

(8) Tiwari, P. K.; Aidhen, I. S. A Weinreb amide based building block for convenient access to  $\beta$ , $\beta$ -diarylacroleins: Synthesis of 3-arylindanones. *Eur. J. Org. Chem.* **2016**, 15, 2637-2646.

(9) Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. *J. Org. Chem.* **1983**, 48, 4155-4156.

(10) Carmosin, R. J.; Carson, J. R.; Pitis, P. M. Preparation of octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents. WO9965911A1.

(11) Assay for inhibition of viral infection as described in the supporting information, run in the presence of 50% NHS, potency reported as a  $EC_{50}$  (average of at least n=2 runs).

(12) Crestey, F.; Witt, M.; Jaroszewski, J. W.; Franzyk, H. Expedited protocol for construction of chiral regioselectively *N*-protected mono-substituted piperazine, 1,4-diazepane building blocks. *J. Org. Chem.*, **2009**, 74, (15), 5652–5655.

(13) Sawamura, M.; Nakayama, Y.; Kato, T.; Ito, Y. Gold(I)catalyzed asymmetric aldol reaction of *N*-methoxy-*N*-methyl- $\alpha$ isocyanoacetamide ( $\alpha$ -isocyano Weinreb amide). An efficient synthesis of optically active  $\beta$ -hydroxy  $\alpha$ -amino aldehydes and ketones. *J. Org. Chem.* **2016**, 15, 2637-2646.

(14) Samanta, K.; Panda, G. Regioselective ring-opening of amino acid-derived chiral aziridines: an easy access to cis-2,5-disubstituted chiral piperazines. *Chem. Asian J.* **2011**, 6, 189 – 197.

(15) Nyasse, B.; Grehn, L.; Ragnarsson, U. Mild, efficient cleavage of arenesulfonamides by magnesium reduction. *Chem. Commun.* **1997**, 11, 1017-1018

(16) Zhan, Z. Preparation of ruthenium complex ligand, ruthenium complexes, supported ruthenium complex catalysts for olefin metathesis, WO 2007003135A1.

(17) Corey, E. J.; Fuchs, P. L. Synthetic method for conversion of formyl groups into ethynyl groups. *Tetrahedron Lett.* **1972**, 36, 3769-72

(18) Sonogashira, K., Development of Pd-Cu catalyzed crosscoupling of terminal acetylenes with sp2-carbon halides. *J. Organomet. Chem.* **2002**, 653, (1-2), 46-49.

(19) Assay for inhibition HIV-1 protease as described in the supporting information, potency reported as an  $IC_{50}$  (average of at least n=2 runs).

## For Table of Contents Only

1

